SCHEMBL19212762

SCHEMBL19212762

CCOC(Cn1c(=O)ccc2ccc(OS(=O)(=O)C(F)(F)F)cc21)OCC

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.38
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
HTR1D P28221 4/20 0.34
DRD2 P14416 4/20 0.34
DRD3 P35462 4/20 0.34
HTR1A P08908 3/20 0.34
HTR1B P28222 3/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
DRD1 P21728 2/20 0.33
DRD4 P21917 2/20 0.33
DRD5 P21918 2/20 0.33
PDE5A O76074 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19212833 0.82 KDM4E (0.37) KDM4EMAPTSMN1; SMN2NPSR1RXFP1
SCHEMBL18264080 0.76 PKM (0.38) KDM4EMAPTSMN1; SMN2NPSR1RXFP1
SCHEMBL19212713 0.76 CDK4 (0.46) KDM4ESMN1; SMN2
SCHEMBL28905831 0.76 HSD11B1 (0.45) HSD11B1DRD2DRD3CA1CA2
SCHEMBL30507256 0.76 HSD11B1 (0.45) HSD11B1DRD2DRD3CA1CA2
SCHEMBL19212863 0.75 ACSS2 (0.39) KDM4E
SCHEMBL28263347 0.74 KMT2A (0.46) KDM4EMAPTPKM
SCHEMBL19212744 0.74 KDM4E (0.41) KDM4ESMN1; SMN2
SCHEMBL19212826 0.71 MEN1 (0.46) KDM4ESMN1; SMN2CA1CA2
SCHEMBL19212630 0.71 JAK3 (0.40) KDM4EMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190055266-A1 HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS REDX PHARMA PLC (GB) 2019-02-21 US disclosed
EP-3413976-A1 HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS Redx Pharma PLC (GB) 2018-12-19 EP disclosed
WO-2017137744-A1 HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS REDX PHARMA PLC (GB) 2017-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055266-A1 HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS OXA1L, OGFOD1, OCIAD2 HSD11B1 1000/4885KDM4E 812/4885MAPT 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.